Compare CCCC & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | LAW |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 259.6M |
| IPO Year | 2020 | 2021 |
| Metric | CCCC | LAW |
|---|---|---|
| Price | $2.74 | $3.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $12.20 | $8.00 |
| AVG Volume (30 Days) | ★ 2.0M | 222.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.45 | ★ 22.58 |
| EPS | N/A | ★ N/A |
| Revenue | $35,947,000.00 | ★ $156,849,000.00 |
| Revenue This Year | N/A | $11.23 |
| Revenue Next Year | N/A | $10.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.02 | ★ 8.29 |
| 52 Week Low | $1.09 | $2.45 |
| 52 Week High | $3.82 | $9.11 |
| Indicator | CCCC | LAW |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 37.28 |
| Support Level | $2.27 | $2.45 |
| Resistance Level | $2.85 | $4.69 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 63.89 | 0.65 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.